Case: 1:17-md-02804-DAP Doc #: 3004-2 Filed: 12/17/19 1 of 4. PageID #: 433524

PSJ4 SOL Opp Exh 32

Case: 1:17-md-02804-DAP Doc #: 3004-2 Filed: 12/17/19 2 of 4. PageID #: 433525

From: Gustin, Dave [/O=MCKESSON/OU=NORTH AMERICA/CN=RECIPIENTS/CN=DAVE GUSTIN]

Sent: 8/31/2011 3:15:43 PM

To: Fagerskog, Dave [dave.fagerskog@mckesson.com]; Rabicke, Ammie [ammie.rabicke@mckesson.com]; Gilmore, Traci

[traci.gilmore@mckesson.com]; Morrison, Tracy [tracy.morrison@mckesson.com]; Hughes, Tom

[tom.hughes@mckesson.com]; Meunier, Kevin [kevin.meunier@mckesson.com]; Van Norman, Christopher

[christopher.vannorman@mckesson.com]; Davis, Nicholas [nicholas.davis@mckesson.com]

CC: Mooney, Scott [scott.mooney@mckesson.com]; Secrest, Larry [larry.secrest@mckesson.com]; Curwin, Anne

[anne.curwin@mckesson.com]; Essensa, Marc [marc.essensa@mckesson.com]; Terry, Tom

[tom.terry@mckesson.com]

BCC: de Gutierrez-Mahoney, Bill [bill.mahoney@mckesson.com]; McDonald, Tom [tom.mcdonald@mckesson.com];

Oriente, Michael [michael.oriente@mckesson.com]; Jonas, Tracy [tracy.jonas@mckesson.com]; Hilliard, Gary

[gary.hilliard@mckesson.com]; Russell, Bruce [bruce.russell@mckesson.com]

Subject: a couple attachments were not sorted right. Here they are again. Project for the next few weeks.

NC team,

I could use your help. I have thought of an area that needs tightened up in CSMP and it is the number of accounts we have that have large gaps between the amount of Oxy or Hydro they are allowed to buy (their threshold) and the amount they really need. (Their current purchases) This increases the "opportunity" for diversion by exposing more product for introduction into the pipeline than may be being used for legitimate reasons. It also makes it look like we are lax about the amount of these drugs we will sell and under what circumstances when we run related reports for the DEA.

To take a look at the attached spreadsheets, please. I ran reports on the region's Oxy and Hydro (base codes 9143 and 9193) thresholds and then began working on the resultant data.

First, I eliminated RNAs and then VAs, then I eliminated all thresholds that were more than 66% MTD as they are obviously being used. Then I eliminated all threshold under 13K per month as they are limited risks. I then eliminated the clutter by getting rid of duplicated info like excess account numbers for the same DEA license.

What I have left on the attached are thresholds that are seemingly higher than need be based on the MTD sales. They are in DC order and then sorted with the biggest gaps in usage first.

If you look at the lists you may be able to make the call to reduce some of the thresholds based on your or the sales person's knowledge of the acct. It some cases a phone call may be needed to ask if the acct is still needing such a high threshold. You need not say what the THD is, just tell them they are only using a fraction of what they are allowed and if that will be the norm you will be reducing the amount. Please share your thoughts? Email me but try not to copy "all" so we do not have an email "free-for-all". I will share as needed. Thx

Dave Gustin DRA North Central

937 840 8553

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

Case: 1:17-md-02804-DAP Doc #: 3004-2 Filed: 12/17/19 3 of 4. PageID #: 433526

From: Hartle, Nathan [/O=MCKESSON/OU=EXCHANGE ADMINISTRATIVE GROUP

(FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=ELYWWE644F]

Sent: 9/9/2014 12:38:52 AM

To: Bishop, Micheal [micheal.bishop@mckesson.com]

CC: Oriente, Michael [michael.oriente@mckesson.com]; Hartle, Nate [nate.hartle@mckesson.com]

Subject: Wakefern Threshold Methodology

Sensitivity: Company Confidential

Bishop – You asked on the call about the methodology we have used in the past so below is what we will use. This will be the same as what we need to do with the new RNA volume for hydrocodone.

• Calculation -

- Buffer We have used in the past so that is what I would put in for now.
- Rounding We will also round up to the nearest
- Additional Adjustments We would then compare the threshold calculation to the number. It there are stores where the threshold is still less than the number. Oriente and I would review and make any decisions.

Does this make sense? Could you add this logic to the spreadsheet for these specific stores?

Thanks, Nate

From: Bishop, Micheal

Sent: Monday, September 08, 2014 4:35 PM

To: Hartle, Nathan; Oriente, Michael **Subject:** RE: For discussion...

The Wakefern file has been saved to the R drive under a newly create RNA folder. Should have all the data elements we discussed...review and let me know if any changes are necessary. Total Rx provided was for 3 months, what I've

included has been normalized for 1 month.

Here's a snapshot of what you'll find based on 75% or above...in yellow are new to what you've already seen.

Chain	Chain Name	Subgroup	Subgroup Name	DEA	Cust Name	DC	Base Code	Base Code Ingredient	R
712	Торко	000240	Wakefern		SHOP RITE PHCY DEPT 649	8155	9143	OXYCODONE	
712	Торсо	000240	Wakefern		SHOP RITE PHCY 227	8191	9143	OXYCODONE	
712	Topco	000240	Wakefern		SHOP RITE PHCY 436	8155	9143	OXYCODONE	
712	Тороо	000240	Wakelern		SHOP RITE PHCY 213	8155	9143	OXYCODONE	
712	Торсо	000240	Wakefern		SHOP RITE PHCY 508	8155	9143	OXYCODONE	
712	Торко	000240	Wakefern		SHOP RITE PHCY DEPT 534	8155	9143	OXYCODONE	
712	Торсо	000240	Wakefern		SHOP RITE PHCY 601	8155	9143	OXYCODONE	
712	Topoo	000240	Wakefern		SHOP RITE PHCY 612	8155	9143	OXYCODONE	
712	Тороо	000240	Wakelern		SHOP RITE PHCY 437	8155	9143	OXYCODONE	
712	Торсо	000240	VVakefern		SHOP RITE PHCY 546	8155	9143	OXYCODONE	
712	Торсо	000240	Wakefern		SHOP RITE PHCY 514	8155	9143	OXYCODONE	
712	Торко	000240	Wakefern		SHOP RITE PHCY 519	8155	9143	OXYCODONE	
712	Topco	000240	Wakefern		SHOP RITE PHCY 572	8155	9143	OXYCODONE	
712	Торсо	000240	Wakelem		SHOP RITE PHCY 663	8155	9143	OXYCODONE	
712	Торсо	000240	VVakefern		SHOP RITE PHCY 288	8191	9143	OXYCODONE	
712	Торсо	000240	VVakefern		SHOP RITE PHCY 655	8155	9143	OXYCODONE	
712	Topco	000240	Wakefern		SHOP RITE PHCY 436	8155	9250	METHADONE	
712	Topco	000240	Wakefern		SHOP RITE PHOY 471	8155	9143	OXYCODONE	
712	Topco	000240	VVakefern		SHOP RITE PHCY DEPT 615	8155	9143	OXYCODONE	
712	Торсо	000240	Wakefern		SHOP RITE PHCY 203	8155	9143	OXYCODONE	
712	Торсо	000240	Wakefern		SHOP RITE PHCY 434	8155	9143	OXYCODONE	

Case: 1:17-md-02804-DAP Doc #: 3004-2 Filed: 12/17/19 4 of 4. PageID #: 433527

				,				
712	Торсо	000240	Wakefern		SHOP RITE PHCY 536	8120	9143	OXYGODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 235	8191	9143	OXYCODONE
712	Торсо	000240	Waketern		SHOP RITE PHCY DEPT 641	8155	9143	OXYCODONE
712	Topco	000240	Wakelern		KLEINS SHOP RITE PHCY 555	8155	9143	OXYCODONE
712	Topco	000240	Wakefern		SHOP RITE PHCY 544	8120	9143	OXYCODONE
712	Topco	000240	Wakefern		SHOP RITE PHCY 651	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 553	8155	9143	OXYCODONE
712	Topco	000240	Wakelem		SHOP RITE PHCY 227	8191	9064	BUPRENORPHINE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 457	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 253	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 507	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		KLEINS SHOP RITE PHCY 545	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY DEPT 659	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 526	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY DEPT 539	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		KLEINS SHOP RITE PHCY 548	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 643	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY DEPT 656	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 665	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY DEPT 504	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 109	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY DEPT 497RX	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 439	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 554	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOPRITE PHY FLANDERS 212	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 281	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 324	8191	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 600	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 450	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY 487	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		SHOP RITE PHCY DEPT 531	8155	9143	OXYCODONE
712	Торсо	000240	Wakefern		KINSLEYS SHOPRITE PHY 422	8155	9143	OXYCODONE

Thank you

Micheal Bishop

O: 972.446.4892 | C: 469.315.8051

From: Hartle, Nathan

Sent: Monday, September 08, 2014 11:46 AM

To: Bishop, Micheal

Subject: RE: For discussion...

Thanks. Let's talk about the Wakefern data in status before we send anything to Bernard. His process is to pull so it will be a different process for him with this one. I will send him a note and cc you on it to see what he thinks.

Nate